BR112022014646A2 - Terapia anti-bcma em transtornos autoimunes - Google Patents

Terapia anti-bcma em transtornos autoimunes

Info

Publication number
BR112022014646A2
BR112022014646A2 BR112022014646A BR112022014646A BR112022014646A2 BR 112022014646 A2 BR112022014646 A2 BR 112022014646A2 BR 112022014646 A BR112022014646 A BR 112022014646A BR 112022014646 A BR112022014646 A BR 112022014646A BR 112022014646 A2 BR112022014646 A2 BR 112022014646A2
Authority
BR
Brazil
Prior art keywords
autoimmune disorders
bcma therapy
bcma
therapy
anca
Prior art date
Application number
BR112022014646A
Other languages
English (en)
Inventor
Mensah Kofi
Plenge Robert
Roy Sophie
Zaller Dennis
Dovey Jennifer
Saenz Steven
Henault Jill
Doykan Camille
Calvino Jenna
Jin Xi
Paquette Joseph
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112022014646A2 publication Critical patent/BR112022014646A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

TERAPIA ANTI-BCMA EM TRANSTORNOS AUTOIMUNES. A presente invenção refere-se ao tratamento ou controle de distúrbios autoimunes, tais como distúrbios autoimunes causados por células de linhagem B autorreativas, por exemplo vasculite associada (AAV) ao anticorpo citoplasmático antineutrófilos (ANCA).
BR112022014646A 2020-02-12 2021-02-11 Terapia anti-bcma em transtornos autoimunes BR112022014646A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062975663P 2020-02-12 2020-02-12
PCT/US2021/017665 WO2021163329A1 (en) 2020-02-12 2021-02-11 Anti-bcma therapy in autoimmune disorders

Publications (1)

Publication Number Publication Date
BR112022014646A2 true BR112022014646A2 (pt) 2022-09-13

Family

ID=77291870

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022014646A BR112022014646A2 (pt) 2020-02-12 2021-02-11 Terapia anti-bcma em transtornos autoimunes

Country Status (11)

Country Link
US (1) US20240052064A1 (pt)
EP (1) EP4103224A4 (pt)
JP (1) JP2023514224A (pt)
KR (1) KR20220141306A (pt)
CN (1) CN115551539A (pt)
AU (1) AU2021221123A1 (pt)
BR (1) BR112022014646A2 (pt)
CA (1) CA3169696A1 (pt)
IL (1) IL295471A (pt)
MX (1) MX2022009784A (pt)
WO (1) WO2021163329A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2963692A1 (en) 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1
WO2023044633A1 (zh) * 2021-09-22 2023-03-30 南京驯鹿医疗技术有限公司 Bcma car-t在制备用于治疗自身免疫病的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA036975B1 (ru) * 2015-08-03 2021-01-21 Энгмаб Сарл Моноклональные антитела против bcma
WO2019089969A2 (en) * 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen

Also Published As

Publication number Publication date
AU2021221123A1 (en) 2022-10-06
KR20220141306A (ko) 2022-10-19
IL295471A (en) 2022-10-01
EP4103224A1 (en) 2022-12-21
EP4103224A4 (en) 2023-08-16
WO2021163329A1 (en) 2021-08-19
CN115551539A (zh) 2022-12-30
JP2023514224A (ja) 2023-04-05
US20240052064A1 (en) 2024-02-15
CA3169696A1 (en) 2021-08-19
MX2022009784A (es) 2022-09-09

Similar Documents

Publication Publication Date Title
BR112022014646A2 (pt) Terapia anti-bcma em transtornos autoimunes
Hakulinen et al. The association between early-onset schizophrenia with employment, income, education, and cohabitation status: nationwide study with 35 years of follow-up
PH12015500435A1 (en) Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions
BR112021006344A2 (pt) vetores de raav para o tratamento de gangliosidose gm1 e gm2
BR112017003505A2 (pt) anticorpos e receptores de antígeno quiméricos específicos para cd19
MX2017013113A (es) Anticuerpos anti-pacap y sus usos.
EA201991643A1 (ru) Человеческие антитела к токсину гемолизину а s.aureus
BR112017019191A2 (pt) métodos para reduzir níveis de soro de agentes que contêm fc utilizando antagonistas de fcrn
BR112022013780A2 (pt) Moléculas de anticorpo para c5ar1 e usos das mesmas
Rasmussen et al. Neurodevelopmental disorders associated with dosage imbalance of ZBTB20 correlate with the morbidity spectrum of ZBTB20 candidate target genes
NI202000005A (es) Agentes, usos y métodos para el tratamiento
BR112022013940A2 (pt) Receptores de antígenos quiméricos para eliminação de amiloides
GB2540895A (en) Hydrogenation of oxygenated molecules from biomass refining
BR112018000155A2 (pt) moléculas de fusão
BR112023001624A2 (pt) Compostos e métodos para reduzir a expressão de app
PA8827501A1 (es) Pirrolidin amidas sustituidas como moduladores del receptor histamina h3
ECSP21046333A (es) Anticuerpos humanizados contra la región de la cadena beta de la 9na familia trbv9 del tcr humano y sus métodos de uso
MX2015009726A (es) Metodo para la prediccion de la aparicion de sintomas extrapiramidales (sep) inducidos por un tratamiento con antipsicoticos.
BR112022001331A2 (pt) Receptor quimérico de antígeno (car) anti-hk2
BR112023000422A2 (pt) Métodos para identificar anticorpos de reação cruzada com coronavírus
MX2023005699A (es) Anticuerpos biespecificos para el uso en el tratamiento de inflamasomopatia nlrc4-gof.
BR112022002142A2 (pt) Anticorpos anti-bdca-2
CL2021003318A1 (es) Compuestos para el tratamiento de trastornos neuromusculares.
Sabatier et al. Community-acquired pneumonia: A 7-years descriptive study. Usefulness of the IDSA/ATS 2007 in the assessment of ICU admission
BR112022016167A2 (pt) Composições e métodos para tratar e prevenir condições associadas à pré-calicreína